The adverse impacts of GRAMD1A in renal clear cell carcinoma largely depend on the immunomodulatory effects of TILs in the tumor microenvironment, which can make it a biomarker for renal diseases[28]. This evidence concerns the gene GRAMD1A and kidney disorder.